 | Up a level |
Koopsen, Jelle; Matthews, Gail; Rockstroh, Juergen; Applegate, Tanya L; Bhagani, Sanjay; Rauch, Andri; Grebely, Jason; Sacks-Davis, Rachel; Ingiliz, Patrick; Boesecke, Christoph; Rebers, Sjoerd; Feld, Jordan; Bruneau, Julie; Martinello, Marianne; Hellard, Margaret; Dore, Gregory J; Schinkel, Janke; van der Valk, Marc (2023). Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis. The Lancet Microbe, 4(8), e622-e631. Elsevier 10.1016/S2666-5247(23)00108-8
Matthews, Gail V; Bhagani, Sanjay; Van der Valk, Marc; Rockstroh, Juergen; Feld, Jordan J; Rauch, Andri; Thurnheer, Christine; Bruneau, Julie; Kim, Arthur; Hellard, Margaret; Shaw, David; Gane, Ed; Nelson, Mark; Ingiliz, Patrick; Applegate, Tanya L; Grebely, Jason; Marks, Phillipa; Martinello, Marianne; Petoumenos, Kathy; Dore, Gregory J; ... (2021). Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of hepatology, 75(4), pp. 829-839. Elsevier 10.1016/j.jhep.2021.04.056
Cunningham, Evan B; Amin, Janaki; Feld, Jordan J; Bruneau, Julie; Dalgard, Olav; Powis, Jeff; Hellard, Margaret; Cooper, Curtis; Read, Phillip; Conway, Brian; Dunlop, Adrian J; Norton, Briana; Litwin, Alain H; Hajarizadeh, Behzad; Thurnheer Zürcher, Maria Christine; Dillon, John F; Weltman, Martin; Shaw, David; Bruggmann, Philip; Gane, Edward; ... (2018). Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International journal of drug policy, 62, pp. 14-23. Elsevier 10.1016/j.drugpo.2018.08.013
Grebely, Jason; Dalgard, Olav; Conway, Brian; Cunningham, Evan B; Bruggmann, Philip; Hajarizadeh, Behzad; Amin, Janaki; Bruneau, Julie; Hellard, Margaret; Litwin, Alain H; Marks, Philippa; Quiene, Sophie; Siriragavan, Sharmila; Applegate, Tanya L; Swan, Tracy; Byrne, Jude; Lacalamita, Melanie; Dunlop, Adrian; Matthews, Gail V; Powis, Jeff; ... (2018). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The lancet. Gastroenterology & hepatology, 3(3), pp. 153-161. Elsevier 10.1016/S2468-1253(17)30404-1
Grebely, Jason; Dalgard, Olav; Cunningham, Evan B; Hajarizadeh, Behzad; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Håvard; ... (2017). Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. The international journal of drug policy, 47, pp. 177-186. Elsevier 10.1016/j.drugpo.2017.05.020
Cunningham, Evan B; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; ... (2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC infectious diseases, 17(1), p. 420. BioMed Central 10.1186/s12879-017-2517-3
